COVID-19 and liver diseases

Bibliographic Information
Authors: Elghannam M.T.; Hassanien M.H.; Ameen Y.A.; ELattar G.M.; ELRay A.A.; Turky E.A.; ELTalkawy M.D.
Journal: Egyptian Liver Journal
Publisher: Springer Science and Business Media Deutschland GmbH
Publication Date: 21 July 2022
Volume / Issue: Volume 12 / Issue 1
Article No.: 43
ISSN: 20906218
DOI: 10.1186/s43066-022-00202-2
Scopus: View on Scopus
Document Type: Review
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Elghannam M.T., Theodor Bilharz Research Institute, Giza, Egypt; Hassanien M.H., Theodor Bilharz Research Institute, Giza, Egypt; Ameen Y.A., Theodor Bilharz Research Institute, Giza, Egypt; ELattar G.M., Theodor Bilharz Research Institute, Giza, Egypt; ELRay A.A., Theodor Bilharz Research Institute, Giza, Egypt; Turky E.A., Theodor Bilharz Research Institute, Giza, Egypt; ELTalkawy M.D., Theodor Bilharz Research Institute, Giza, Egypt
Abstract
Coronavirus causes an outbreak of viral pneumonia that spread throughout the world. Liver injury is becoming more widely recognized as a component of the clinical picture of COVID-19 infection. Hepatitis with serum ALT elevation has been reported in up to half of patients. Patients with CLD were at a higher risk of decompensation with liver failure, hospitalization, and mortality. The percentage of acute liver injury (ALI) varied from 5 to 28%. COVID-19 hinders HCV elimination by 2030. It is recommended to continue treatment of chronic HCV and chronic HBV if already receiving treatment. Consider using antiviral therapy to prevent viral flare-ups in patients with occult or resolved HBV and COVID-19 who are receiving immunosuppressive agents. Patients with AIH do not have an increased risk of adverse outcomes even in high-risk areas. There is an association between MAFLD and disease progression. Patients with any type of cancer are at a higher risk of infection and are more likely to develop more severe clinical outcomes. Most societies advise against immunosuppressant modifications in patients with mild COVID-19, whereas in rare cases such as severe lymphopenia, worsening pneumonia, or bacterial or fungal superinfection, reduction or discontinuation of antiproliferative agents and lymphocyte-depleting therapies has been suggested. © 2022, The Author(s).
Keywords
Autoimmune liver disease; Coronaviruses; COVID-19 vaccination; Hepatocellular carcinoma; Liver diseases; Liver transplantation; SARS-CoV-2
Citation Information
Scopus Citations: 6
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
